EF Hutton initiated coverage of UroGen Pharma with a Buy rating and $25 price target The firm believes UroGen’s stock “is on the cusp of a breakout,” driven by expansion to the broader cancer-urology market with new products UGN102 and URGN103. EF sees a $5B for both candidates.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- UroGen Pharma Announces CFO Transition and Compensation Details
- UroGen Pharma CFO Don Kim departs, Chris Degnan succeeds
- UroGen Pharma: Patient dosed in mitomycin-based UGN-103 trial for LG-IR-NMIBC
- UroGen Pharma receives new U.S. patent allowance for RTGel technology
- UroGen Pharma management to meet with Oppenheimer